Fig. 3: U0126 inhibitor blocks noncanonical Erk kinase activity induced by IL-17. | Laboratory Investigation

Fig. 3: U0126 inhibitor blocks noncanonical Erk kinase activity induced by IL-17.

From: TGFβ1-Smad canonical and -Erk noncanonical pathways participate in interleukin-17-induced epithelial–mesenchymal transition in Sjögren’s syndrome

Fig. 3: U0126 inhibitor blocks noncanonical Erk kinase activity induced by IL-17.The alt text for this image may have been generated using AI.

The effect of Erk inhibitor U0126 on Erk 1 and Erk 2 genes expression was quantified by semiquantitative RT-PCR (a, b) and real-time PCR (c) in untreated healthy SGEC, in healthy SGEC treated for 24 h with IL-17, and in SGEC treated with IL-17 plus U0126. d, e Western blotting analysis of Erk 1/2 and p-Erk1/2 protein expression in cultured healthy SGEC treated for 48 h with IL-17 and in SGEC treated with IL-17 + U0126; untreated healthy SGEC were used as control. As expected, cotreatment with IL-17 plus U0126 blocks the activation of Erk1/2. Bands intensities were analyzed by densitometric analysis performed by gel image software, normalized against that of GAPDH for RT-PCR (b) and β-actin for western blotting, and expressed in arbitrary units (e). (Data represent mean ± SE; n = 3). Asterisks and arrowheads indicate statistical significance p < 0.01. M Marker.

Back to article page